Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmpt.2021.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re: Goertz et al. Extrapolating Beyond the Data.
J Manipulative Physiol Ther
October 2021
Clinical Education, Canadian Memorial Chiropractic College; Family & Community Medicine, St. Michael's Hospital, Toronto, Ontario, Canada. Electronic address:
Re. Goertz et al. Extrapolating beyond the data.
J Manipulative Physiol Ther
October 2021
Canadian Memorial Chiropractic College, Toronto, Canada. Electronic address:
Extrapolating Beyond the Data in a Systematic Review of Spinal Manipulation for Nonmusculoskeletal Disorders: A Fall From the Summit.
J Manipulative Physiol Ther
May 2021
Health, RAND Corporation, Santa Monica, California.
Objective: The purpose of this article is to discuss a literature review-a recent systematic review of nonmusculoskeletal disorders-that demonstrates the potential for faulty conclusions and misguided policy implications, and to offer an alternate interpretation of the data using present models and criteria.
Methods: We participated in a chiropractic meeting (Global Summit) that aimed to perform a systematic review of the literature on the efficacy and effectiveness of mobilization or spinal manipulative therapy (SMT) for the primary, secondary, and tertiary prevention and treatment of nonmusculoskeletal disorders. After considering an early draft of the resulting manuscript, we identified points of concern and therefore declined authorship.
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Value Health
April 2019
Genentech, Inc., South San Francisco, USA.
Objective: The APHINITY trial assessed the effectiveness and the safety of adding pertuzumab to trastuzumab and chemotherapy (THP) compared to trastuzumab and chemotherapy (TH) in the adjuvant management of human epidermal growth factor 2-positive (HER2+) breast cancer. We performed a study to project the potential cost-effectiveness of THP vs. TH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!